Search

everythinglearnresearchcommunity

for

Search:↓

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Enzyme booster SULT1A1 greatly enhances hair regrowth with minoxidil.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Early diagnosis and treatment of myositis in SLE patients lead to better outcomes.

JAK inhibitors may help improve symptoms in adults with APECED.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Ocrelizumab may cause total body hair loss in some patients.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

The combination therapy was effective and well-tolerated, especially in young patients.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Early diagnosis and treatment of myositis in SLE patients lead to positive outcomes.

Adequate steroid treatment needed to limit bone loss in PMR patients.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.